Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 21.03
(2.14%)
CNY 21.03
(2.14%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.64 Billion CNY | -32.38% |
| 2022 | 2.43 Billion CNY | 6.41% |
| 2021 | 2.28 Billion CNY | 21.09% |
| 2020 | 1.88 Billion CNY | 34.02% |
| 2019 | 1.4 Billion CNY | 29.98% |
| 2018 | 1.08 Billion CNY | 4.81% |
| 2017 | 1.03 Billion CNY | 4.06% |
| 2016 | 993.2 Million CNY | 12.23% |
| 2015 | 885 Million CNY | 54.58% |
| 2014 | 572.53 Million CNY | 53.03% |
| 2013 | 374.12 Million CNY | 21.41% |
| 2012 | 308.14 Million CNY | 78.27% |
| 2011 | 172.84 Million CNY | 15.3% |
| 2010 | 149.91 Million CNY | 39.77% |
| 2009 | 107.26 Million CNY | 28.24% |
| 2008 | 83.64 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.53 Billion CNY | -6.85% |
| 2024 Q2 | 1.45 Billion CNY | -4.74% |
| 2024 Q3 | 1.44 Billion CNY | -0.76% |
| 2023 Q4 | 1.64 Billion CNY | -29.22% |
| 2023 Q3 | 2.32 Billion CNY | -8.05% |
| 2023 FY | 1.64 Billion CNY | -32.38% |
| 2023 Q2 | 2.52 Billion CNY | 2.81% |
| 2023 Q1 | 2.45 Billion CNY | 1.07% |
| 2022 Q3 | 2.61 Billion CNY | 1.25% |
| 2022 Q2 | 2.57 Billion CNY | 5.81% |
| 2022 FY | 2.43 Billion CNY | 6.41% |
| 2022 Q1 | 2.43 Billion CNY | 6.66% |
| 2022 Q4 | 2.43 Billion CNY | -6.88% |
| 2021 Q1 | 1.9 Billion CNY | 0.77% |
| 2021 FY | 2.28 Billion CNY | 21.09% |
| 2021 Q2 | 2.08 Billion CNY | 9.43% |
| 2021 Q4 | 2.28 Billion CNY | -0.4% |
| 2021 Q3 | 2.29 Billion CNY | 10.26% |
| 2020 FY | 1.88 Billion CNY | 34.02% |
| 2020 Q1 | 1.62 Billion CNY | 15.67% |
| 2020 Q2 | 1.76 Billion CNY | 8.3% |
| 2020 Q3 | 1.87 Billion CNY | 6.52% |
| 2020 Q4 | 1.88 Billion CNY | 0.44% |
| 2019 Q1 | 1.15 Billion CNY | 6.32% |
| 2019 FY | 1.4 Billion CNY | 29.98% |
| 2019 Q2 | 1.28 Billion CNY | 11.64% |
| 2019 Q3 | 1.35 Billion CNY | 5.23% |
| 2019 Q4 | 1.4 Billion CNY | 4.06% |
| 2018 Q2 | 1.07 Billion CNY | 3.45% |
| 2018 FY | 1.08 Billion CNY | 4.81% |
| 2018 Q4 | 1.08 Billion CNY | 1.08% |
| 2018 Q3 | 1.07 Billion CNY | -0.71% |
| 2018 Q1 | 1.04 Billion CNY | 0.95% |
| 2017 Q4 | 1.03 Billion CNY | -8.31% |
| 2017 FY | 1.03 Billion CNY | 4.06% |
| 2017 Q3 | 1.12 Billion CNY | 3.35% |
| 2017 Q2 | 1.09 Billion CNY | 9.1% |
| 2017 Q1 | 999.64 Million CNY | 0.65% |
| 2016 Q4 | 993.2 Million CNY | 0.46% |
| 2016 Q2 | 968.69 Million CNY | 4.37% |
| 2016 Q1 | 928.14 Million CNY | 4.87% |
| 2016 FY | 993.2 Million CNY | 12.23% |
| 2016 Q3 | 988.62 Million CNY | 2.06% |
| 2015 Q3 | 769.63 Million CNY | 11.79% |
| 2015 Q2 | 688.43 Million CNY | 10.51% |
| 2015 Q1 | 622.95 Million CNY | 8.81% |
| 2015 FY | 885 Million CNY | 54.58% |
| 2015 Q4 | 885 Million CNY | 14.99% |
| 2014 Q4 | 572.53 Million CNY | -7.07% |
| 2014 FY | 572.53 Million CNY | 53.03% |
| 2014 Q2 | 594.05 Million CNY | 46.87% |
| 2014 Q1 | 404.48 Million CNY | 8.12% |
| 2014 Q3 | 616.1 Million CNY | 3.71% |
| 2013 Q2 | 316.82 Million CNY | 2.32% |
| 2013 Q4 | 374.12 Million CNY | 9.86% |
| 2013 Q3 | 340.55 Million CNY | 7.49% |
| 2013 FY | 374.12 Million CNY | 21.41% |
| 2013 Q1 | 309.63 Million CNY | 0.48% |
| 2012 Q1 | 172.01 Million CNY | -0.48% |
| 2012 FY | 308.14 Million CNY | 78.27% |
| 2012 Q2 | 257.72 Million CNY | 49.83% |
| 2012 Q3 | 253.61 Million CNY | -1.6% |
| 2012 Q4 | 308.14 Million CNY | 21.5% |
| 2011 Q3 | 216.14 Million CNY | 17.63% |
| 2011 Q2 | 183.74 Million CNY | 0.0% |
| 2011 Q4 | 172.84 Million CNY | -20.03% |
| 2011 FY | 172.84 Million CNY | 15.3% |
| 2010 FY | 149.91 Million CNY | 39.77% |
| 2010 Q4 | 149.91 Million CNY | 0.0% |
| 2009 FY | 107.26 Million CNY | 28.24% |
| 2008 FY | 83.64 Million CNY | 0.0% |